SIC 2835 – In Vitro and In Vivo Diagnostic Substances
Valuation | |
---|---|
Market Cap ($M) | 144.92 |
Enterprise Value ($M) | 136.51 |
Book Value ($M) | 83.38 |
Book Value / Share | 2.04 |
Price / Book | 1.74 |
NCAV ($M) | 1.38 |
NCAV / Share | 0.03 |
Price / NCAV | 104.71 |
Profitability (mra) | |
---|---|
Return on Invested Capital (ROIC) | -0.31 |
Return on Assets (ROA) | -0.27 |
Return on Equity (ROE) | -0.42 |
Liquidity (mrq) | |
---|---|
Quick Ratio | 3.92 |
Current Ratio | 5.52 |
Balance Sheet (mrq) ($M) | |
---|---|
Current Assets | 38.82 |
Assets | 120.82 |
Liabilities | 37.44 |
Debt | n/a |
Equity | n/a |
Income Statement (mra) ($M) | |
---|---|
Revenue | 36.68 |
Operating Income | -31.20 |
Net Income | -36.78 |
Cash Flow Statement (mra) ($M) | |
---|---|
Cash From Operations | -18.70 |
Cash from Investing | -7.74 |
Cash from Financing | 12.80 |
(click for more detail) |
File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
---|---|---|---|---|
13D | Telegraph Hill Partners IV, L.P. | 70.80 | 47.21 |
Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
---|---|---|---|---|
(click for more detail) |
Date | Insider Trades | Code | Shares | Value |
---|---|---|---|---|
(click for more detail) |
File Date | Form | SEC Filings |
---|---|---|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q | ||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K | ||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q | ||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q | ||
(click for more detail) |
Short Volume | |||
---|---|---|---|
Market Date | Short Volume | Total Volume | Short Volume Ratio |
165,292 | 702,907 | 23.52 | |
204,789 | 742,926 | 27.57 | |
2,278,958 | 7,646,488 | 29.80 | |
101,249 | 530,206 | 19.10 | |
1,805,614 | 5,789,610 | 31.19 | |
(click for more detail) |
Similar Companies | |
---|---|
TBPH – Theravance Biopharma, Inc. | TCRX – TScan Therapeutics, Inc. |
TENK – TenX Keane Acquisition | TLPH – Talphera, Inc. |
TNGX – Tango Therapeutics, Inc. |
Financial data and stock pages provided by
Fintel.io